Cargando…
Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer
BACKGROUND: Gemcitabine/cisplatin (GP) resistance displays a negative role in treating advanced and metastatic non-small cell lung cancer (NSCLC). Several studies found that the association existed between platelets and cancer antigen 125 (CA125) with anticancer drugs. But the exact correlation betw...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284361/ https://www.ncbi.nlm.nih.gov/pubmed/30498189 http://dx.doi.org/10.12659/MSM.911125 |
_version_ | 1783379320833572864 |
---|---|
author | Shi, Liang Li, Yiming Yu, Tingting Wang, Zeng Zhou, Chenxi Xing, Wenxiu Xu, Gaoqi Tong, BingLei Zheng, Yingchao Zhou, Jie Huang, Ping |
author_facet | Shi, Liang Li, Yiming Yu, Tingting Wang, Zeng Zhou, Chenxi Xing, Wenxiu Xu, Gaoqi Tong, BingLei Zheng, Yingchao Zhou, Jie Huang, Ping |
author_sort | Shi, Liang |
collection | PubMed |
description | BACKGROUND: Gemcitabine/cisplatin (GP) resistance displays a negative role in treating advanced and metastatic non-small cell lung cancer (NSCLC). Several studies found that the association existed between platelets and cancer antigen 125 (CA125) with anticancer drugs. But the exact correlation between GP resistance and platelet activation index remains poorly understood. MATERIAL/METHODS: Pre-chemotherapy platelet activation index and CA125 were retrospectively evaluated in 169 advanced and metastatic NSCLC patients. All variables were screened by chi-square test and then evaluated by log-rank test. Survival curves were generated by Kaplan-Meier analysis. Univariate and multivariate survival analysis were performed by using Cox proportional hazards model. RESULTS: The overall rate of GP resistance for NSCLC patients was 72.19%. Mean platelet volume (MPV) and plateletcrit (PCT) are negative predictors of GP resistance adenocarcinoma [Odds ratio (OR): 5.81, 95% confidence interval (CI): 1.082–31.195, P=0.004] and squamous cell carcinoma (PCT: R: 3.517, 95% CI: 1.087–11.387, P=0.036), respectively. But both were an independent factor associated with overall survival (OS). Moreover, only CA125 was a dependent factor associated with OS for squamous cell carcinoma [OS: hazard ratio (HR): 1.741, 95% CI: 1.002–3.024, P=0.049; GP resistance: OR: 4.862, 95% CI: 1.437–16.448, P=0.011]. CONCLUSIONS: Platelet activation index will be a potential marker for predicting GP resistance. Besides, CA125 ≥16.9 could be used as a potential marker for predicting GP resistance and OS, which was more sensitive than CA125 ≥35 for squamous cell carcinoma. |
format | Online Article Text |
id | pubmed-6284361 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-62843612018-12-28 Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer Shi, Liang Li, Yiming Yu, Tingting Wang, Zeng Zhou, Chenxi Xing, Wenxiu Xu, Gaoqi Tong, BingLei Zheng, Yingchao Zhou, Jie Huang, Ping Med Sci Monit Clinical Research BACKGROUND: Gemcitabine/cisplatin (GP) resistance displays a negative role in treating advanced and metastatic non-small cell lung cancer (NSCLC). Several studies found that the association existed between platelets and cancer antigen 125 (CA125) with anticancer drugs. But the exact correlation between GP resistance and platelet activation index remains poorly understood. MATERIAL/METHODS: Pre-chemotherapy platelet activation index and CA125 were retrospectively evaluated in 169 advanced and metastatic NSCLC patients. All variables were screened by chi-square test and then evaluated by log-rank test. Survival curves were generated by Kaplan-Meier analysis. Univariate and multivariate survival analysis were performed by using Cox proportional hazards model. RESULTS: The overall rate of GP resistance for NSCLC patients was 72.19%. Mean platelet volume (MPV) and plateletcrit (PCT) are negative predictors of GP resistance adenocarcinoma [Odds ratio (OR): 5.81, 95% confidence interval (CI): 1.082–31.195, P=0.004] and squamous cell carcinoma (PCT: R: 3.517, 95% CI: 1.087–11.387, P=0.036), respectively. But both were an independent factor associated with overall survival (OS). Moreover, only CA125 was a dependent factor associated with OS for squamous cell carcinoma [OS: hazard ratio (HR): 1.741, 95% CI: 1.002–3.024, P=0.049; GP resistance: OR: 4.862, 95% CI: 1.437–16.448, P=0.011]. CONCLUSIONS: Platelet activation index will be a potential marker for predicting GP resistance. Besides, CA125 ≥16.9 could be used as a potential marker for predicting GP resistance and OS, which was more sensitive than CA125 ≥35 for squamous cell carcinoma. International Scientific Literature, Inc. 2018-11-30 /pmc/articles/PMC6284361/ /pubmed/30498189 http://dx.doi.org/10.12659/MSM.911125 Text en © Med Sci Monit, 2018 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) ) |
spellingShingle | Clinical Research Shi, Liang Li, Yiming Yu, Tingting Wang, Zeng Zhou, Chenxi Xing, Wenxiu Xu, Gaoqi Tong, BingLei Zheng, Yingchao Zhou, Jie Huang, Ping Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer |
title | Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer |
title_full | Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer |
title_fullStr | Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer |
title_full_unstemmed | Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer |
title_short | Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer |
title_sort | predictable resistance and overall survival of gemcitabine/cisplatin by platelet activation index in non-small cell lung cancer |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284361/ https://www.ncbi.nlm.nih.gov/pubmed/30498189 http://dx.doi.org/10.12659/MSM.911125 |
work_keys_str_mv | AT shiliang predictableresistanceandoverallsurvivalofgemcitabinecisplatinbyplateletactivationindexinnonsmallcelllungcancer AT liyiming predictableresistanceandoverallsurvivalofgemcitabinecisplatinbyplateletactivationindexinnonsmallcelllungcancer AT yutingting predictableresistanceandoverallsurvivalofgemcitabinecisplatinbyplateletactivationindexinnonsmallcelllungcancer AT wangzeng predictableresistanceandoverallsurvivalofgemcitabinecisplatinbyplateletactivationindexinnonsmallcelllungcancer AT zhouchenxi predictableresistanceandoverallsurvivalofgemcitabinecisplatinbyplateletactivationindexinnonsmallcelllungcancer AT xingwenxiu predictableresistanceandoverallsurvivalofgemcitabinecisplatinbyplateletactivationindexinnonsmallcelllungcancer AT xugaoqi predictableresistanceandoverallsurvivalofgemcitabinecisplatinbyplateletactivationindexinnonsmallcelllungcancer AT tongbinglei predictableresistanceandoverallsurvivalofgemcitabinecisplatinbyplateletactivationindexinnonsmallcelllungcancer AT zhengyingchao predictableresistanceandoverallsurvivalofgemcitabinecisplatinbyplateletactivationindexinnonsmallcelllungcancer AT zhoujie predictableresistanceandoverallsurvivalofgemcitabinecisplatinbyplateletactivationindexinnonsmallcelllungcancer AT huangping predictableresistanceandoverallsurvivalofgemcitabinecisplatinbyplateletactivationindexinnonsmallcelllungcancer |